Australian researchers spearhead paradigm shift in melanoma treatment
20 September 2021
In what has been described as a paradigm shift in the treatment of melanoma, drug therapy looks set to become the standard treatment for high-risk early stage melanoma patients to stop disease spread and save lives.
Promising results from an international multi-centre clinical trial, which included researchers and patients from Melanoma Institute Australia (MIA), were presented this weekend at the prestigious European Society for Medical Oncology (ESMO) Congress.
Results showed giving high-risk Stage II melanoma patients the same immunotherapy drugs approved for use in advanced melanoma patients, reduced the risk of their disease returning or death by 35%.
Study author Professor Georgina Long AO, Co-Medical Director of Melanoma Institute Australia and of The University of Sydney, said the findings would result in a paradigm shift in treatment of early stage patients.
‘We are using drug therapy already proven to be life-saving for advanced melanoma patients, to stop the disease in its tracks in earlier stage patients,’ Professor Long said. ‘These exciting clinical trial results are strong evidence to support approval for this immunotherapy to become standard treatment for high-risk Stage II patients in Australia.’
The clinical trial demonstrated that giving pembrolizumab (Keytruda™) after surgery to patients with Stage IIB or IIC melanoma (deemed at high risk of spread due to tumour thickness or ulceration) reduced the risk of the disease returning or death by 35% compared to placebo. At 12 months, only 9.5% of patients on pembrolizumab had their melanoma progress, compared to 16.9% in the placebo group.
In the last decade, the approval of immunotherapy for Stage III and IV melanoma patients has dramatically increased survival rates, with more than 50% of these patients now essentially cured.
However, there are no immunotherapy drugs currently approved for use in Stage II melanoma patients. They instead have to adopt a ‘watch-and-wait’ approach after surgery to see if their cancer will return or spread. Patients with thick Stage II melanoma also often undergo an invasive Sentinel Node Biopsy to check for disease spread, with drug therapy only available once their disease has spread to their lymph nodes (Stage III).
Fellow study author Professor Richard Scolyer AO, Co-Medical Director of Melanoma Institute Australia and of The University of Sydney, says the clinical trial results stand to transform how earlier stage disease is managed.
‘By giving this immunotherapy treatment at an earlier stage, we are proactively preventing melanoma spread,’ Professor Scolyer said.
Australia has the highest melanoma rates in the world with one person diagnosed with the disease every 30 minutes. An estimated 1300 Australians are expected to die from melanoma this year.
Following these clinical trial results, it is hoped pembrolizumab will soon come before the Pharmaceutical Benefits Advisory Committee (PBAC) for approval for use in these patients in Australia.
‘This proactive approach to preventing disease spread represents a significant step forward in our mission of reaching zero deaths from melanoma,’ Professor Scolyer added.
The full data set was presented at ESMO on Saturday 18 September 2021 at 11:05pm (AEST) by Associate Professor Jason Luke in a presentation entitled: “Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the Keynote 716 double-blinded phase III trial”.
Melanoma Institute Australia is affiliated with The University of Sydney and Professor Scolyer and Professor Long lead the Translational Research Group at the Charles Perkins Centre.
Jennifer Durante |email@example.com | 0412 798 990
The 2021 Australasian Melanoma Conference (AMC2021) will held in Sydney, Australia.
Drug therapy set to become standard treatment in high-risk early stage patients to stop disease spread
We are excited to announce a return to our much-loved physical Melanoma March events in March 2022!
Over two fun, yet challenging, days in September an intrepid group of riders and crew successfully completed the annual Melanoma Bike Bash in WA!
Prof Long AO has been recognised by Australian Academy of Health and Medical Sciences for her transformative work advancing melanoma treatments.
Three MIA researchers at University of Sydney received grants to further their important melanoma research.
COVID restrictions continue to impact fundraising for melanoma services in Riverina.
Ben Garrow lost his life to melanoma. In his honour his family has established a scholarship to support a PhD student whose work focuses on saving lives from melanoma.
More than 150 clinicians, researchers and MIA staff gathered online to share research highlights.
Independent researchers at The University of Sydney are seeking patient feedback.
A re-cap of the wonderful, and often very creative, community fundraising initiatives over the April to June quarter.
Our patients who donate their tissue samples and records to our research are helping to make a difference to the lives of future melanoma patients.
MIA researchers have recently been awarded two competitive funding grants, which will help facilitate their ground-breaking work in melanoma research.
Celebrate the 10th anniversary of Amie St Clair Melanoma at the Annual Ball in Wagga Wagga!
Postponed to early 2022. Melanoma survivor Matt Kean is doing a 1000km bike ride around the Riverina to increase awareness of melanoma and raise funds for Amie St Clair Melanoma - MIA. There are many ways you can be part of this life-changing ride!
Riverina patients gain access to potentially life saving immunotherapy treatment close to home.
MIA's Prof Scolyer has been appointed as an Officer (AO) of the Order of Australia.
In a breakthrough which could extend to the treatment of other cancers, a new immune checkpoint inhibitor has proven effective in helping save the lives of advanced melanoma patients.
Whilst our research and clinical teams are trialling new treatments to save lives, it is our nurses who are on the front line providing care and support.